hydrocortisone plus fludrocortisone
Phase 3Small molecule
hydrocortisone plus fludrocortisone is one of 62 small molecule programs targeting Septic Shock. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Septic Shock
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Merrem
BB. Braun Medical Inc.
Approved
Duragesic
CCephalon
Approved
Florinef
Jazz PharmaceuticalsPhase 3
Osmitrol
BB. Braun Medical Inc.
Approved
Integrilin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac Surgery1 trial
Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery
Not yet recruiting·—·Phase 3·NCT07037043·196 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details